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s u m m a r y 
Objectives: To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay 
(cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further 
to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for 
responses against the whole S protein. 
Methods: Serum samples from 30 patients were assayed for anti-NP responses, for ‘neutralisation’ by the 
surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising 
two target cell lines. Correlation between assays was measured using linear regression. 
Results: The responses observed within the surrogate neutralisation assay demonstrated an extremely 
strong, highly significant positive correlation with those observed in both pseudotyped virus assays. 
Conclusions: The tested ELISA-based surrogate assay provides an immunologically useful measure of func- 
tional immune responses in a much quicker and highly automatable fashion. It also reinforces that de- 
tection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral 
infection. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 



































SARS-CoV-2, the aetiological agent of COVID-19 disease, has 
een the focus of intense research efforts since its emergence 
n late 2019. Development of clinical interventions and diagnos- 
ic tools has proceeded at a rapid pace. However, as we move to- 
ards the deployment of widespread vaccination programmes, ad- 
itional challenges will emerge. An important aspect moving for- 
ard will be the capacity for long term monitoring of the func- 
ional immune response against SARS-CoV-2 at a population level. 
hilst SARS-CoV-2 infection is known to elicit potent neutralis- 
ng antibody responses, these can wane within the span of a few 
onths, particularly in those who only suffer a mild infection. 1 , 2 
owever, an independent study demonstrated that whilst antibody 
itres may drop the specific neutralising activity of the antibody re- 
ponse improves between 1 and 6 months post infection. Further- ∗ Corresponding authors. 
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 http://creativecommons.org/licenses/by/4.0/ ) ore, the authors reported stable levels of circulating memory B 
ells suggesting that individuals will be better protected upon re- 
xposure – a fundamental principle of immunological memory. 3 , 4 
hese studies exemplify the importance of monitoring antibody re- 
ponses and, furthermore, the quality of the antibody response. To 
ate, antibody titres can be assessed by commercial assays but, of- 
en, the antibodies measured in these assays are typically those 
hat target the nucleocapsid protein (NP), and no attempt is made 
o measure how functional these responses are. 
A more immunologically relevant viral target for antibodies is 
he SARS-CoV-2 surface glycoprotein spike (S). The S protein facil- 
tates binding to human angiotensin-converting enzyme-2 (ACE-2) 
ia its receptor-binding domain (RBD). 5–8 The isolation of various 
ighly potent monoclonal antibodies directed against the RBD rein- 
orces the importance of this particular region of the S protein. 9–11 
onsequently, long term monitoring of specifically neutralising an- 
ibody levels against S protein, or just the RBD, is likely to provide 
 more clinically useful measure of functional immunity against 
ARS-CoV-2. This is heightened even further by the fact that vac- 
ine development has logically focused on generating immune re- ion Association. This is an open access article under the CC BY license 










































































































ponses against the S protein, 12–15 and thus these responses would 
ot be detected by an NP-specific assay. 
Ideally, neutralising antibody responses would be assayed by 
easuring the ability of patient sera to prevent infection of phys- 
ologically relevant target cells (e.g. primary lung epithelial cells) 
y SARS-CoV-2. However, this requires a high level of expertise, 
quipment and containment facilities, and is not feasible on a large 
cale. An attractive alternative is the generation of pseudotyped 
iruses, often used in vitro for genetic modification of cells, which 
re produced from a combination of multiple plasmids and thus 
annot propagate in isolation. 16 Although this approach does have 
imitations it does allow specific analysis of antibody responses 
gainst S protein in a more high-throughput manner. 
Whilst pseudotyped viruses represent a highly tractable middle 
round between studying fully infectious SARS-CoV-2 and studying 
roteins in isolation, they still require a level of expertise to utilise 
ffectively, are vulnerable to biological and experimental variation 
nd assays that employ them can take over 24 h, potentially ex- 
ending to multiple days to return results. Thus, a validated mea- 
ure of neutralising antibody responses against S protein that could 
e measured in a simple rapid ELISA-type assay has important 
mplications for large scale rapid assessment of antibody activity. 
hus our remit was to determine whether a commercially avail- 
ble ELISA-type surrogate virus neutralisation kit (Genscript cPass 
ARS-CoV-2 Surrogate Virus Neutralization Kit), which claims to 
pecifically measure neutralising antibodies against SARS-CoV-2 S 
BD was capable of: a) detecting neutralising antibody responses 
n serum samples confirmed positive for antibodies against NP, 
) whether those responses correlated with those determined by 
seudotyped virus neutralisation assay and therefore c) whether 
easuring responses solely against the RBD of S protein is indica- 
ive of responses against the S protein as presented in a viral con- 
ext. 
During the course of our own studies, it was reported that 
sing a similar approach, evidence of correlation between the 
urrogate virus neutralisation assay and neutralisation of both 
ARS-CoV-2 S pseudotyped viruses and wildtype SARS-CoV-2 was 
hown. 17 However, we note that in the prior study that the authors 
sed a VSV-pseudotyped virus and performed the study in vero 
ells. Given the increasing uncertainty around the use of vero cells 
s a reliable model of aspects of SARS-CoV-2 entry, 18 we completed 
ur own analyses with an alternative pseudotyping (lentivirus) sys- 
em and, importantly, using human cells expressing TMPRSS2 as 
argets for infection. 
ethods 
ell culture conditions 
Hela cells constitutively expressing ACE2 (Hela-ACE2, a kind gift 
rom James Voss 19 ) and 293T/17 (ATCC CRL-11,268) cells were in- 
ubated at 37 °C at 5% CO 2 in DMEM (Gibco) supplemented with 
0% fetal calf serum and 100 U/ml penicillin/streptomycin cocktail. 
ample acquisition and preparation 
A panel of anonymous residual serum samples surplus to di- 
gnostic requirements from the Royal Free archive (as such use of 
hese sera is exempt from specific ethical approval) were used to 
ndertake the neutralisation assay assessment. These samples were 
reviously classified as positive ( n = 15) and negative ( n = 15) for
ARS-CoV-2 nucleocapsid antibody serology using the Roche Elec- 
ys Anti-SARS-CoV-2 Assay. Testing was performed as per manu- 
acturer’s instructions. 
Samples were heat inactivated by treatment at 56 °C for 30 min 
rior to usage in any further assays. 171 urrogate viral neutralisation assay (SVN assay) 
Serum samples were tested for neutralising activity using the 
ARS-CoV-2 Surrogate Virus Neutralization Test Kit (cPass Assay, 
enscript) as per manufacturer’s instructions. Briefly, samples and 
rovided positive and negative controls were diluted 1:10 with 
rovided Sample Dilution Buffer. 125 μl of sample/control was then 
ixed 1:1 with HRP-RBD solution and incubated at 37 °C for 
0 min. 100 μl of each sample/control was added to the provided 
ACE2 coated plate in technical duplicate. Plate was sealed and 
ncubated at 37 °C for 15 min. Wells were then washed 4x with 
00 μl of provided Wash Solution. 100 μl provided TMB solution 
as added per well and the plate incubated in the dark at room 
emperature for 15 min. 50 ul of provided Stop Solution was added 
er well to quench reaction, and absorbance at 450 nm was read 
mmediately (Thermo Scientific Multiskan FC Microplate Photome- 
er). 
Data was analysed as per manufacturer’s instructions. Relative 
nhibition was calculated by the equation: 
nhibition = 
(
1 − OD v alue of Sample 
Mean OD v alue of Negati v e Control 
)
∗100 
Values ≥20 were considered positive for neutralisation (as per 
anufacturer’s instructions), whilst those < 20 were considered 
egative. Samples were ranked in order from highest relative in- 
ibition to lowest. 
The confidence interval for assay sensitivity was computed by 
he Wilson-Brown method within Graphpad Prism software. 
ARS-CoV-2 pseudotyped virus production 
Solutions of the required plasmids and transfection reagents 
ere prepared thusly: 0.6 μg of pcDNA3.1-SARS-CoV-2-S (a kind 
ift of Nigel Temperton, University of Kent), 0.6 μg of pCMV8.91 
nd 0.9 μg of pCSFLW were incubated in 50 μl OptiMEM for 5 min. 
 μl of TransIT-293 (Mirus) was added to 50 μl OptiMEM (Gibco) 
nd incubated for 5 min. Transfection reagent and plasmid mix 
ere then combined and mixed by inversion. Mixture was incu- 
ated at room temperature for 20 min with occasional inversion, 
ollowed by dropwise addition to 70% confluent 293T/17 cells in 
 ml DMEM (Gibco) in a 6-well plate. Four hours post addition, 
.5 ml additional DMEM was added to cells. Supernatant was har- 
ested 48 h post transfection, spun at 500 g for 5 min to remove 
ell debris, and stored at −80 °C. 
ransfection of cells 
5 μg of pCAGGS-ACE2 and 500 μg of pCAGGS-TMPRSS2 were in- 
ubated in 500 μl OptiMEM for 5 min. 15 μl of TransIT-293 (Mirus) 
as added to 500 μl OptiMEM and incubated for 5 min. Transfec- 
ion reagent and plasmid mix were then combined and mixed by 
nversion. Mixture was incubated at room temperature for 20 min 
ith occasional inversion, followed by dropwise addition to 60% 
onfluent 293T/17 cells in a 100 mm dish. Cells were utilised 48 h 
ost transfection. 
ARS-CoV-2 neutralisation assay 
SARS-CoV-2 pseudotyped virus (a previously established quan- 
ity sufficient to produce 40 0,0 0 0 RLU in 293T/17 cells transfected 
ith TMPRSS2 and ACE2) was treated in a total volume of 100 μl 
ith serial dilutions of sera or media only control for 1 h at 
7 °C in a 96-well plate format. Then, 2.5 × 10 4 Hela-ACE2 cells or 
.5 × 10 4 293T/17 + ACE2/TMPRSS2 (in 100 μl) were added to each 
ell.After 48 h, media was removed, cells washed with PBS and 
ells lysed with a 1:1 mixture of complete media and Bright-Glo 























































































































uciferase reagent (Promega). After 5 min, luciferase activity was 
ead out using a luminometer (GloMax 96 Microplate Luminome- 
er, Promega). Virus + cells only and cells only controls were in- 
luded on each plate to allow for normalisation of luminescence 
cross multiple plates. 
nalysis of pseudotyped virus data 
Data from pseudotyped virus infection of Hela-ACE2 cells was 
anked based on endpoint criteria, to reflect the measurements 
sed in the SVN cPass assay. Those samples capable of reducing 
uciferase activity by > 95% at a higher dilution than others were 
anked more highly (e.g. a sample that reduced by > 95% at 1:80 
as ranked higher than one that reduced by > 95% at 1:40 but 
ot at 1:80). Samples that reduced by > 95% at the same dilution 
ere ranked relative to one another based on their absolute per- 
ormance at the lowest dilution at which they did not display a 
eduction of at least 95% (e.g. Sample A and sample B reduce by 
 95% at 1:20, but sample A reduces by 90% at 1:40 and sample B
y 80% at 1:40. Sample A would rank higher than sample B). Sam- 
les that could reduce luciferase activity by > 95% at 1:10 dilution 
ere considered positive for neutralisation, whilst those that could 
ot were considered negative. 
Due to the increased dynamic range of the assay available in 
93T/17 + ACE2/TMPRSS2 cells, performance in the pseudotyped 
irus neutralisation assay was assessed by multiple criteria: Half 
omplete neutralisation dilution (ND 50 , i.e. the dilution at which 
he serum was capable of reduced the luciferase signal by 50% of 
he activity observed in the absence of serum), 90% complete neu- 
ralisation dilution (ND 90 ) and maximum inhibition (i.e. level of in- 
ibition observed in the least dilute, 1:10 condition). ND 50 was cal- 
ulated using GraphPad Prism software, and ND 90 calculated using 
he resultant ND 50 and Hill slope (H) values by the equation: 
 D 90 = N D 50 
(
10 
100 − 10 
)1 /H 
Samples were then ranked for each criterion according to their 
bsolute performance. Correlation between different sets of ranked 
riteria was assessed within GraphPad Prism software by simple 
inear regression or Spearman’s correlation. Correlation between 
ets of raw data was performed using nonparametric Spearman’s 
orrelation within GraphPad Prism software. 
esults 
To perform our analyses, we first collected a bank of sera sam- 
les previously assayed for the presence of SARS-CoV-2 nucleo- 
apsid protein (NP) reactive antibodies. Fifteen samples were con- 
rmed to be positive for antibodies to NP, whilst the remaining 15 
amples were confirmed to be negative ( Fig 1 A). The serostatus of 
he samples established by this assay was taken to be the baseline 
o which all following data was compared. Sera were then heat 
nactivated and tested in parallel in both surrogate (SVN cPass) 
nd pseudoviral neutralisation (PVN) assays (total summary of data 
vailable in Figure S1). 
The 30 samples were analysed in the SVN cPass assay, in which 
eutralisation is assessed by the ability of the sera to block binding 
f HRP-conjugated SARS-CoV-2 S receptor binding domain (RBD) 
o a human ACE-2-coated ELISA plate ( Fig. 1 B). Application of the 
anufacturer’s advised cut-off of 20% resulted in 11 samples re- 
orting as unambiguously positive for ‘neutralisation’, with a fur- 
her sample considered ambiguously positive (technical replicates 
ying either side of the cut-off, but with an average neutralisation 
f 21%). 
The remaining 18 test samples were considered negative, in ad- 
ition to the provided negative control. Importantly, all 15 sam- 
les considered negative by the NP assay were also negative in the 172 VN cPass assay. Therefore, 3 samples considered positive by NP 
ssay were returned as negative by the SVN assay. This could ei- 
her represent false negatives or represent individuals whom failed 
o generate an effective neutralising response to the S protein upon 
ARS-CoV-2 infection. We note that two of these samples (#22 and 
23) did register positive values below the manufacturer’s cut-off
f 20% (4.8% and 12.8%, placing them 14th and 12th in the SVN 
eutralisation ranking respectively), whilst all but 1 negative sam- 
les (#9 being the exception) registered negative values (i.e. most 
egative samples had an ELISA OD reading above that of the pro- 
ided negative control). One interpretation is that the kit did detect 
 level of neutralising activity in these samples, but it was below 
he limit of sensitivity. The third ‘false negative’ (#5) performed ex- 
remely poorly, demonstrating less neutralisation than 12 negative 
amples. By this analysis, the SVN kit demonstrated a sensitivity of 
0% (95% C.I.: 0.548–0.930) and a specificity of 100% based on NP 
ntibody titres. 
Next, we investigated whether SVN cPass assay performance 
orrelated with responses against NP protein. Initially, we com- 
ared the raw values produced by the two assays for only those 
amples considered to be positive for NP reactive antibodies by 
wo measures: by correlation and by simple linear regression 
 Fig 1 C). This resulted in a correlation coefficient, r, of 0.668 (95% 
I: 0.0.221–0.883, p = 0.008) and an R 2 value of 0.409 ( p = 0.0 0 01)
espectively. Ranked data was also plotted directly and tested by 
imple linear regression for clarity ( Fig 1 D, R = 0.668). When these 
nalyses were extended to include those samples negative for NP- 
eactive antibodies ( Fig 1 D/E), the correlation increased to r = 0.848 
95% CI 0.694–0.926, p < 0.0 0 01) and the R 2 value for simple lin-
ar regression increased to 0.669 ( p < 0.0 0 01). Whilst these corre- 
ations are all highly significant, the relatively poorer performance 
hen only considering samples positive for NP-reactive antibodies 
s likely indicative of the fact the assays test for different antibody 
unctions; namely, ability to bind NP protein against claimed abil- 
ty to prevent S protein RBD from binding the ACE2 receptor. 
In order to assess whether the SVN cPass assay was genuinely 
apable of providing a reliable measure of neutralising activity, 
he same samples were used in two SARS-CoV-2 lentiviral pseu- 
otyped virus neutralisation (PVN) assays, employing different tar- 
et cells. Sera samples were serially diluted and mixed with pseu- 
ovirus particles bearing SARS-CoV-2 S envelope proteins, before 
he addition of either SARS-CoV-2 receptor ACE2-expressing Hela 
ells, or 293T/17 cells transfected to transiently express ACE2 and 
MPRSS2. Successful entry into the cell by the virus resulted in in- 
egration of a luciferase-expressing lentivirus construct, whose ac- 
ivity could be read out using standard luciferase techniques. Sam- 
les were then ranked according to criteria described in the meth- 
ds. 
Summary data demonstrating the ND 50 , ND 90 and maximum 
esponse data generated from the infection of ACE2/TMPRSS2- 
xpressing 293T/17 cells can be found in Fig 2 A–C. The data indi- 
ate that all samples that were positive for NP antibodies demon- 
trated more potent neutralisation than all but one of the negative 
amples (#9), all with ND 50 values in excess of 25 (i.e. a 1:25 di- 
ution of serum could reduce luciferase activity by at least 50%). 
ample #9 demonstrated significant neutralising activity, with an 
D 50 value of 60.0 and an ND 90 value of 30.2, scoring higher than 
 and 8 NP-positive samples by each of these measures respec- 
ively. This is the same sample in which a below cut off degree 
f neutralisation was observed in the SVN assay, suggesting that 
his sample does indeed harbour detectable neutralising capacity 
gainst S. Additionally, sample #5 performed poorly by all mea- 
ures of neutralisation (ranking behind all other samples from pos- 
tive individuals and sample #9 in ND 50 and maximum response 
alues, and also behind a ‘negative’ sample in ND 90 rankings). 
he extremely poor neutralisation demonstrated by this sample in 
M.J. Murray, M. McIntosh, C. Atkinson et al. Journal of Infection 82 (2021) 170–177 
Fig. 1. Neutralising activity in a surrogate virus neutralisation assay correlates with anti-nucleocapsid protein titre. 
(A)Serum samples from 30 individuals was tested for antibodies against SARS-CoV-2 nucleocapsid protein (NP) by Elecsys® Anti-SARS-CoV-2 assay. Those in red were 
considered positive for anti-SARS-CoV-2-NP antibodies, and are shown as such throughout the figure. (B) Serum samples from (A) were tested for neutralising activity by an 
ELISA-type surrogate virus neutralisation (SVN) assay. The cutoff represents the manufacturer’s advised value of 20% (i.e. a 20% reduction in signal compared to the negative 
control). Values shown as mean ± SD. (C) Comparison between raw data from NP and SVN assays. Data was assessed by both Spearman correlation and by simple linear 
regression. The red line indicates the best fit linear regression line for NP-positive samples only, whilst the black line represents the best fit line for all data points. (D,E) 
Samples were ranked according to their NP antibody titre and neutralisation in the SVN and plotted for clarity. These ranks were then compared by simple linear regression. 









































he PVN assay recapitulates what was observed in the SVN cPass 
ssay. 
To judge the performance of the SVN cPass assay against the 
VN assay, the performances of the samples were compared by 
pearman correlation and plotted in both raw and ranked form 
 Fig 3 ). Comparison between inhibition in the SVN cPass assay and 
eciprocal ND 50 values ( Fig 3 A/B) by only NP-reactive samples re- 
ulted in a Spearman correlation coefficient of r = 0.946 (95% CI 
.838–0.983, p < 0.0 0 01). Comparison between SVN cPass assay 
nd reciprocal ND 90 values for NP-reactive samples ( Fig 3 C/D) pro- 
uced a similarly strong correlation ( r = 0.911, 95% CI 0.739–0.971, 
 < 0.0 0 01), Even when employing a very blunt measure of perfor-
ance within the PVN assay, namely the maximum response, cor- 
elation was extremely strong for these samples ( r = −0.872, 95% 
I −0.958 to −0.641, p < 0.0 0 01). This strongly suggests that the 
VN does provide a genuine measure of neutralisation against the 
 protein. Expanding these analyses to include samples negative 
or NP-reactive antibodies (Ranked plots in Fig S1A-C) results in 
nly a small change in correlation (ND 50 , r = 0.871, 95% CI 0.739–
.939, p < 0.0 0 01, ND 90 r = 0.874, 95% CI 0.746–0.940, p < 0.0 0 01
nd maximum response r = 0.874, 95% CI, p < 0.0 0 01). We also ob-173 erved that when limited to positive samples only ( Fig 3 G/H), PVN 
D 50 values did not significantly positively correlate with anti-NP 
ntibody titre ( r = 0.504, 95% CI −0.028 to 0.813, p = 0.058). Whilst
nclusion of the negative samples ( Figs. 3 G and S1D) led to a highly
ignificant correlation ( r = 0.847, 95% CI 0.694–0.926, p < 0.0 0 01), 
his relatively poor correlation reinforces the notion that these ap- 
roaches are designed to detect different aspects of the antibody 
esponse to SARS-CoV-2 infection. 
Finally, to further interrogate the suitability of the SVN assay as 
 surrogate measure of antibody neutralising activity in sera, we 
epeated the PVN in Hela cells transduced to stably express ACE2. 
his approach allowed us to characterise the SVN assay to an in- 
ependent cell line, with lower ACE2 expression and without TM- 
RSS2 overexpression. Luciferase activity was much lower follow- 
ng infection of Hela-ACE2 cells in comparison to the transfected 
93T/17 cells, and consequentially increased noise in the data ren- 
ered ND 50 values a poor method of ranking the data. However, 
lear neutralisation could still be observed, and so samples were 
herefore ranked according to the dilution at which they could no 
onger reduce luciferase expression by at least 95% ( Fig 4 A, see 
ethods). By this approach, all samples that were positive for NP 
M.J. Murray, M. McIntosh, C. Atkinson et al. Journal of Infection 82 (2021) 170–177 
Fig. 2. Assessment of neutralising activity of patient serum by pseudovirus assay. 
SARS-CoV-2 S pseudotyped virus was incubated with a series of serum dilutions 
for 1 h prior to infection of 293T/17 cells transiently expressing ACE2 and TMPRSS2. 
Forty-eight hours post infection, luciferase activity (RLU) was readout as a measure 
of infection. Points in red were considered positive for anti-SARS-CoV-2-NP anti- 
bodies, and are shown as such throughout the figure. (A) Summary of dilutions at 
which serum could reduce RLU by 50% (ND 50 ) compared to untreated controls. (B) 
Summary of dilutions at which serum could reduce RLU by 90% (ND 90 ) compared to 













































































ntibodies were positive for neutralisation (could reduce luciferase 
ctivity by 95% at a 1:10 dilution or higher), as well as one neg-
tive sample (#9, the same sample that demonstrated neutralis- 
ng activity in the 293T/17 PVN assay and limited neutralisation in 
he SVN assay). The best performing negative sample only demon- 
trated a 61.7% reduction in luciferase activity at a 1:10 dilution. 
hese rankings were once again correlated against the rankings 
rom the SVN cPass assay, demonstrating a positive correlation co- 
fficient of 0.636 (95% CI 0.167–0.870, p = 0.0128) for positive sam- 
les only ( Fig 4 B), which increased to 0.822 (95% CI 0.650–0.914, 
 < 0.0 0 01) when expanded to include all samples ( Fig 4 C). Thus,
egardless of the cell type used for the PVN assay, the readout of 
eutralisation activity through both approaches was highly correl- 
tive. We noted particularly poor correlation between NP-reactive 
ntibody titre rankings and rankings in the Hela-ACE2 PVN assay 174 or NP-positive samples ( r = 0.143, 95% CI −0.413 to 0.621) ( Fig 4 D),
hich was again increased by the inclusion of negative samples as 
bserved previously ( r = 0.755, 95% CI 0.534–0.879). 
iscussion 
Given the level of diagnostic activity surrounding the study of 
amples from COVID-19 patients, there is a pressing need for easily 
mployable, automatable assays that go further than simply mea- 
uring total antibody titres against particular antigens. Whilst these 
an provide useful information, they do not constitute functional 
eadouts of antibody activity. However, assays that can measure 
ntibody functions such as neutralisation or capacity to trigger 
ntibody-dependant cellular cytotoxicity (ADCC) typically involve 
 need for cell culture and associated biological procedures that 
re no longer routine in a diagnostic setting. 20 , 21 Here we have 
emonstrated that a commercially available surrogate virus neu- 
ralisation assay produces data that strongly correlates with data 
rom pseudotyped virus neutralisation assays, that itself has been 
hown to strongly correlate with wild-type, authentic SARS-CoV- 
 neutralisation assays, and consequently could be employed for 
ass screening of individuals’ sera to measure the prevalence and 
ntensity of neutralising antibody responses in a high-throughput 
anner against an important vaccine target – the S protein of 
ARS-CoV-2. 
The ability to screen large numbers of sera samples is likely to 
ecome increasingly useful as mass vaccination programmes be- 
in to be rolled out worldwide – particularly if the virus becomes 
ndemic requiring seasonal vaccination. Thus, assays such as this 
rovide an opportunity for population-level monitoring of the neu- 
ralising antibody response present in these vaccinated individu- 
ls over time and may help to establish the requirement for ad- 
itional doses of the vaccine at later time points – particularly in 
ulnerable patient groups. Whilst neutralising antibody responses 
re not the only immunologically relevant measure of vaccine effi- 
acy, they are more readily measurable in large quantities of sam- 
les in comparison to measurements of e.g. virus-specific CD4 + or 
D8 + cells. 22–24 Furthermore, assays such as this are far more rel- 
vant in a vaccination setting than the currently employed anti-NP 
pproach, as most vaccines in development are designed to elicit 
rotective immune responses against the S protein. 15 It is worth 
oting that the accuracy of this assay would require monitoring 
n the context of emerging variants, particularly those with multi- 
le mutations in the RBD. 25–27 However, the simplicity of the assay 
hould render testing of multiple RBD-HRP constructs, if required, 
eadily achievable. 
An additional insight from our study is comparison of how 
trongly neutralising responses against the whole S protein pre- 
ented in the context of a virus particle correlate with responses 
gainst only the RBD. This is promising for the development of 
urther diagnostic tools to measure relevant responses against the 
 protein, as use of only the RBD may be required, simplifying the 
roduction process and removing the need to produce stable forms 
f full length S protein in the absence of a lipid membrane to em- 
ed into. 
However, we note that a previous study published during the 
ourse of our analyses suggested that the correlation between the 
wo approaches was low. 17 Reasons for the difference are unclear. 
lthough a different pseudotyped virus backbone was used there 
s no obvious technical reason why differences would occur. A ma- 
or difference was the use of Vero cells in the prior study rather 
han the human ACE-2 transfected cells used here. Entry into Vero 
ells is clearly sensitive to neutralising antibodies, but the precise 
echanisms differ – a difference that led to the aberrant espousal 
f hydroxychloroquine as an antiviral. 18 , 28 Essentially in our sys- 
em Spike is processed at the plasma membrane which may make 
M.J. Murray, M. McIntosh, C. Atkinson et al. Journal of Infection 82 (2021) 170–177 
Fig. 3. Ability of patient sera to neutralise SARS-CoV-2 pseudovirus correlates strongly with neutralisation observed in SVN assay. 
Data from Fig. 2 was plotted against the observed inhibition in the SVN assay and correlation assessed by Spearman correlation. Samples were then ranked according to the 
criteria in Fig. 2 and plotted against one another for clarity. Points in red were considered positive for anti-SARS-CoV-2-NP antibodies, and are shown as such throughout 
the figure. (A,B) ND 50 values were correlated against inhibition observed in the SVN assay. (A) Represents raw values, whilst (B) demonstrates ranked values from only 
NP-positive samples. (C,D) ND 90 values were correlated against inhibition observed in the SVN assay. (C) Represents raw values, whilst (D) demonstrates ranked values from 
only NP-positive samples. (E,F) Maximum Response values were correlated against inhibition observed in the SVN assay. (E) Represents raw values, whilst (F) demonstrates 
ranked values from only NP-positive samples. (G,H) ND 50 values were correlation against anti-NP antibody titre. (G) represents raw values, whilst (H) represents ranked 
values from only NP-positive samples. 
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M.J. Murray, M. McIntosh, C. Atkinson et al. Journal of Infection 82 (2021) 170–177 
Fig. 4. Surrogate neutralisation reported in SVN assay correlates with ability to prevent infection of Hela cells stably expressing ACE2. 
(A) SARS-CoV-2 S pseudotyped virus was incubated with a series of serum dilutions for 1 h prior to infection of Hela-ACE2 cells. Forty-eight hours post infection, luciferase 
activity (RLU) was readout as a measure of infection. Data shown indicates the RLU (compared to 100 for untreated pseudovirus) at the lowest serum dilution at which 
RLU was reduced by at least 95% (i.e. below 5). (B) Samples from NP-positive only donors or (C) samples from all donors were ranked as described based on data from and 
correlated with ranked performance in SVN by simple linear regression. (D,E) PVN ranking was compared to NP titre ranking for NP-positive only donors (D) or all donors 

































t more susceptible to antibody recognition and more likely reflects 
he route of natural infection. 
A second point of caution (based on our analyses) over the sur- 
ogate virus neutralisation assay was the observed sensitivity of 
0% which may actually be too stringent for characterising serosta- 
us. However, optimisation of the process and, in particular, of 
he cut-off value (generated via the value of the negative control) 
ould likely improve this and can be incorporated into future as- 
ay standardisation and quality control. Additionally, all samples 
ere subjected to heat inactivation prior to use to remove com- 
onents of the complement system for the PV neutralisation assay. 
lthough we analysed the same sera in both assays this is not re- 
uired for the SVN cPass assay and may have led to a minor level
f antibody degradation, thus contributing to this reduced sensi- 
ivity. Whilst the kit currently does not claim to be suitable for 
uantitative analysis of neutralising responses, the strong correla- 
ions observed between performance in SVN and PVN suggest that 176 t could be utilised for this purpose – if used alongside appropri- 
te standards. In vivo there are always degrees of neutralising re- 
ponses to target proteins, even in the absence of cognate infec- 
ion, and evidence of a weak level of neutralisation does not in- 
icate evidence of effective neutralisation, thus employing these 
ools in a quantitative manner is likely to be more informative 
particularly if longitudinal samples from individuals are taken, e.g. 
o monitor for decline in responses following vaccination) than ap- 
lying a simple yes/no cut-off. 
Although the focus of our study was to validate the SVN cPass 
ssay we were intrigued by the identification of an individual with 
pparent neutralising activity against S protein (albeit quite low) 
hich was considered negative by nucleocapsid assays. Whether 
his reflects a more potent response against S protein in that 
ndividual or, possibly, the presence of cross-reactive antibodies 
gainst the spike proteins of circulating seasonal coronaviruses is 
ot clear. 29 , 30 However, the SVN cPass assay is focused on the RBD 



























































hich, in analyses thus far, has not been identified as a major tar- 
et of cross-neutralising antibodies and thus we cannot rule out 
 non-specific serum effect active in this sample. Additionally, the 
ature of the sampling means we cannot associate samples with 
ime of infection, and it has been shown that a positive test by 
oche assay is more robust later into the infection course than 
pike serology. Unfortunately, the anonymisation of the samples 
eans that this individual cannot be followed up with further tests 
o see if they become positive on the Roche assay. 
The inherent nature of the samples (anonymised residual di- 
gnostic samples) is a source of limitation to the study. Little is 
nown about the disease status and the proportion of which are 
rom otherwise healthy asymptomatics – information that cannot 
e identified retrospectively in this study. Furthermore, there is no 
irect testing against live virus on primary cells although the pseu- 
otype approach as a surrogate has been extensively characterised 
or this and other infections. 31 , 32 
In summary, ELISA-type surrogate virus neutralisation assays, 
uch as the Genscript cPass assay evaluated here, have the poten- 
ial to reflect physiologically relevant neutralisation of SARS-CoV-2 
sing human cells expressing ACE-2 and TMPRSS2. Consequently, 
heir ability to be automated and performed rapidly renders them 
 highly potent diagnostic tool for the ongoing monitoring of func- 
ional immune responses against the pandemic virus, at both the 
ndividual and particularly at the population level. 
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